

DAFTAR PUSTAKA

1. Adao R, Keulenaer G, Moreira AL, Silva CB. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention. *Portuguese Journal of Cardiology*.2013;32:395-409.
2. Albini A, Pennesi G, Donatelli F, Cammarota R, Flora SD, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio oncology and cardio oncological prevention. *Journal National Cancer Institute*.2010;102:14-25.
3. Jessup M, Shaikh, Dallen V. Off Target: Chemotherapeutics and cardiovascular system anthracyclines induces cardiomyopathy. *Current Heart Failure Revision*.2012;9:117.
4. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. *Journal American Medical Association*.1991;266:1672-7.
5. Prima R. Korelasi Nilai Troponin T dan Nilai Fungsi Diastolik Menggunakan Tissue Doppler Imaging Pada Pasien Kanker Payudara Yang Mendapatkan doxorubisin. Tesis. Repository Universitas Andalas.2014:35.
6. Data Riset Kesehatan Dasar. Badan litbangkes kementerian kesehatan RI dan data penduduk sasaran. Pusdatin Kementerian Kesehatan Republik Indonesia.2013:2-3.
7. Rekam Medis Rumah Sakit M Djamil Padang. Data pasien kanker payudara tahun 2012-2016. Padang. 2016.
8. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. National comprehensive cancer network. *Clinical Practice Guideline in Oncology Breast Cancer*.2015;1:47.
9. Swain SM. Doxorubisin induced cardiomyopathy. *New England Journal Medicine*.1999;340:654-655.
10. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems. *Clinical Cancer Research*.2008;14:14-24.
11. Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment. *Journal Clinical Oncology*.2002; 30:3657-3664.
12. Singal PK, Hiskovic N. Doxorubisin induced cardiomyopathy. *New England Journal Medicine*.1998;339:900-905.
13. Yeh ET, Tong AT, Lenihan DJ, Yusuf W, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: Diagnosis, Pathogenesis and Management.*Circulation*.2004;109:3122-3131.
14. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubisin cardiotoxicity in lymphoma patients. *British Journal of Cancer*.2002;86:1967-700.
15. Schmitt K, Tulzer G, Merl M, Aichorn G, Grillenberger A, Wiesinger G. Early detection of doxorubisin and daunorubicin cardiotoxicity by echocardiography : Diastolic versus systolic parameters. *European Journal Pediatrics*.1995;154(3):201-4.
16. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubisin: Retrospective Analysis of Three Trials. *Cancer*.2003;97:2869-79.

17. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al. Subclinical late cardiomyopathy after doxorubisin therapy for lymphoma in adults. *Journal Clinical Oncology*.2004;22:1864 –1871.
18. Muggia FM, Speyer JL. Doxorubisin induced cardiomyopathy. *New England Journal Medicine*.1999;340:654–655.
19. Cardinale D, Colombo A, Sandri MT, Giuseppina Lamantia G, Colombo N, Maurizio Civelli M, et al. Prevention of high risk chemotherapy induced cardiotoxicity in high risk patients by angiotensin converting enzyme Inhibition. *Circulation*.2006;114:2474–81.
20. Boucek RJ Jr, Steele A, Miracle A. Effects of angiotensin converting enzyme inhibitor on delayed onset doxorubisin induced cardiotoxicity. *Cardiovascular Toxicology*.2003;3:319–329.
21. Hunt SA, Abraham WT, Chin MH. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a Report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. *Journal American College Cardiology*.2009;53:1343–82.
22. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, Giacomiet GD, et al. Anthracycline induced cardiomyopathy. Clinical relevance and response to pharmacologic therapy. *Journal American College Cardiology*.2010;55:213–20.
23. Sacco G, Bigioni M, Evangelista S. Cardioprotective effects of zofenopril, a new angiotensin converting enzyme inhibitor on doxorubisin induced cardiotoxicity in the rat. *European Journal Pharmacology*.2001;414:71–8
24. Vaynblat M, Shah HR, Bhaskaran D. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubisin. *European Journal Heart Faillure*.2002;4:583–6.
25. Bosch X, Rovira M, Sitges M, Domenechet A. Enalapril and carvedilol for preventing chemotherapy induced left ventricular systolic dysfunction in patients with malignant hemopathies. *Journal of the American College of Cardiology*.2013;61:2355-2356.
26. Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensin converting enzyme inhibitor for epirubicin induced dilated Cardiomyopathy. *Lancet*.1996 ; 347:297-9.
27. Schimmel K, Richel D, Brink R. Cardiotoxicity of cytotoxic drugs. *Cancer Treatment Reviews*.2009;30:181–191.
28. Jensen BV ST, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity : a Prospective, blinded, long term observational study of outcome in 120 patients. *Annual Oncology*.2002;13:699-709.
29. Vergely C DS, Cottin Y, Rochett L. Preventing the cardiotoxic effects of anthracyclines: From basic concepts to clinical data. *Heart Metabolic*. 2007;35:1-7.
30. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacology Revision*.2004;56:185–229.
31. Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side effects of cancer chemotherapy. *International Journal of Cardiology*.2010;144:3-15.

32. Caulfield JB, Bittner V. Cardiac matrix alterations induced by adriamycin. *American Journal of Pathology*.1988;133:298-305.
33. Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos MA, et al. Endothelial vascular toxicity from chemotherapeutic agents: Preclinical Evidence and Clinical Implications. *Cancer Treatment Reviews*.2012;38:473–83.
34. Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. *Molecular pharmacology*. 2005;68:261–71.
35. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. *Journal of Molecular and Cellular Cardiology*.2012.1217.
36. Vedam K, Nishijima Y, Druhan LJ, Khan M, Moldovan NI, Zweier JL, et al. Role of heat shock factor-1 activation in the doxorubicin induced heart failure in mice. *American Journal Physiology Heart Circulation*. *Physiology*. 2010;298:1832–41.
37. Shan YX, Liu TJ, Su HF, Samsamshariat A, Mestrlil R, Wang PH. Hsp 10 and Hsp 60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin cardiac muscle cells. *Journal Molecular Cell Cardiology*.2003;35:1135–43.
38. Maejima Y, Adachi S, Morikawa K, Ito H, Isobe M. Nitric oxide inhibits myocardial apoptosis by preventing caspase 3 activity via s-nitrosylation. *Journal Molecular Cell Cardiology*.2005;38:163–74.
39. Viale PH, Yamamoto DS. Cardiovascular toxicity associated with cancer treatment. *Clinical Journal Oncology*.2008;12:627-38.
40. Newby LK, Rodriguez I, Finkle J, Becker RC, Hicks KA, Hausner E, et al. Troponin measurements during drug development considerations for monitoring and management of potential cardiotoxicity: An Educational collaboration among the cardiac safety research consortium, the duke clinical research institute, and the US food and drug administration. *American Heart Journal*.2011;162:64-73.
41. Sendon JL, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. *European Heart Journal*.2004;25:1454–1470.
42. Okumura K, Jin D, Takai S, Miyazaki M. Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. *Japan Journal Pharmacology*.2002;88:183-188.
43. Hahn VS, Lenihan DJ, Bonnie K. Cancer therapy induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. *Journal of the American Heart Association*. 2014: 4-5.
44. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: Role of an intracardiac renin angiotensin system. *Annual Review Physiology*. 1992;54: 227–241.
45. Toko H, Oka T, Zou Y, Sakamoto M, Mizukami M, Sano M, et al. Angiotensin II type Ia receptor mediates doxorubicin induced cardiomyopathy. *Hypertension Research*.2002;25:597–603.

46. Georgakopoulos P, Roussou P, Matsakas E, Karavidas A. Cardioprotective effect of metoprolol and enalapril in doxorubisin treated lymphoma patients: a Prospective, parallel group, randomized, controlled study with 36 month follow-up. *American Journal Hematology*.2010.85:894-896.
47. Nakamae H, Tsumura K, Terada Y, Nakane T, Nakane T, Nakamae M, et al. Notable effects of angiotensin II receptor blocker, valsartan on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubisin, vincristine, and prednisolone. *Cancer*.2005;104:2492–2498.
48. Iqbal M, Dubey K, Anwer T, Ashish A, Pillai K. Protective effects of telmisartan against acute doxorubisin-induced cardiotoxicity in rats. *Journal Pharmacological*.2008;60:382-390.
49. Hahn VS, Lenihan DJ, Ky B. Cancer therapy–induced cardiotoxicity: Basic mechanisms and potential cardioprotective therapies. *Journal of the American Heart Association*.2014;3:3-4.
50. Qamar R, Carerj S, Khandheria BK, Paterick TE. Use of echocardiography to evaluate the cardiac effects of therapies used in cancer treatment: what do we know?. *Journal American Society Echocardiography*.2012;25:1141-52.
51. Fallah RN, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. *Journal American College Cardiology*.2011;57:2263-70.

